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Anaphylaxis is a life-threatening event that can occur anytime during pregnancy. It has been reported following administration
of various substances with adverse maternal and neonatal consequences. It should be considered in the diﬀerential diagnosis
of intrapartum collapse. We encountered a case of severe anaphylactic reaction following a routine cesarean section. It is very
important that all members of the perinatal team are aware of early recognition and management of anaphylactic reaction. We
think that it is important to highlight this as a further case report of severe anaphylactic reaction to a colloid solution and discuss
the pathophysiology and management.
Copyright © 2009 K. Karri et al.Thisisanopenaccess articledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Anaphylaxis is an acute systemic reaction with life-
threatening consequences. Anaphylaxis although uncom-
mon can lead to adverse maternal and fetal consequences
if it occurs during pregnancy. It can be severe, can occur
within minutes after initial exposure to the oﬀending agent,
and can occur with no history of known allergy. In United
States, it has been estimated that 1 to 17% of the population
are at risk of anaphylaxis and of these 0.002% are at
risk of fatal reactions [1]. Incidence among inpatients has
been reported to be 3–5 per 10000 [2]. The estimated
incidence of intra-operative anaphylaxis is between 1:3500
and 1:20000 [3, 4]. Anaphylaxis can result in signiﬁcant
long-termmorbidity,mainlyrelatedtocerebralhypoxiaafter
an ineﬀective resuscitation. It is very important that the
members of the perinatal team are aware of the symptoms
and signs of anaphylactic reaction and are familiar with
the management of anaphylactic shock. We report a case of
anaphylactic reaction to Volplex, a commonly used colloid
solution, in the immediate postoperative period following
cesarean section and reviewed the literature on pregnancy
and anaphylaxis.
2. Case History
A 34-year-old primigravida underwent a cesarean section
for failed induction of labour under spinal anesthesia. She
booked with a Body mass Index of 31. She was diabetic on
insulinandwasonmethyldopainviewofessentialhyperten-
sion. The surgery was uneventful until the very end. Towards
the end of the procedure, the systolic component of the
blood pressure dropped to 85mmHg. She was given 500mL
of Volplex, a gelatin-based colloid. Within few minutes, she
developedtingling,itchingaroundfaceincludingtongueand
lips. Then she complained of diﬃculty in breathing and
blood pressure dropped to 65mmHg systolic. The colloid
was stopped. She was given adrenaline 100µg intravenously
and following that she was given hydrocortisone 100mg and
chlorphenaramine 10mg. With these medications, the blood
pressure improved and there was marked improvement in
her symptoms. She was well oxygenated and did not need
intubation. She responded well to resuscitation and was
transferred to Intensive care unit. Serum tryptase was sent
one hour postincident and was 41.6 which is consistent with
anaphylaxis. Repeat value of Tryptase on the next day was 11.
She had no previous incidents of anaphylaxis and no history
of any known allergies. Skin prick testing to ascertain the2 Obstetrics and Gynecology International
causative agent was undertaken and anaphylactic reaction
due to a gelatin-based colloid was conﬁrmed.
3.Pathophysiology
Anaphylaxis is a rapid systemic hypersensitivity reaction to
a substance in a sensitised individual with potentially life-
threatening consequences. Anaphylaxis is mediated by IgE
antibodies, which can cause histamine and other vasoactive
mediators to be released from mast cells and basophills
[5]. IgE immunoglobulins are found in plasma and are the
only antibodies in man to produce anaphylactic reactions,
for example, immediate hypersensitivity. The antibodies are
generated on exposure to a deﬁned stimulus. These Mast
cells are wandering cells that are found in most tissues but
are most abundant in connective tissue. These cells liberate
histamine in the tissues as part of the inﬂammatory reaction.
These mediators produce respiratory, circulatory, cutaneous,
and gastrointestinal eﬀects. Increased vascular permeability
and peripheral vasodialation reduce venous return and
cardiac output. A mild reaction is manifested as Flushing,
urticaria, redness, and localized oedema. More serious
reaction is manifested as shock, bronchospasm, laryngeal
oedema, and angioedema. Anaphylactic reaction is usually
precipitated by blood products, vaccines, insect bites, latex
rubber,skinantiseptics,andcertaindrugssuchasantibiotics,
Opioid analgesics, and neuromuscular blocking agents. It
is more likely to occur after parenteral administration and
atopic individuals are particularly susceptible because of
their hereditary predisposition to anaphylactic reactions.
4. ClinicalManifestations
Symptoms can vary in onset, appearance, and course.
Cardiovascular and cutaneous symptoms are more common
and account for about three quarters of the manifestations
(see Table 1). Mild reactions are manifested in the form of
pruritus,rash,ﬂushingoftheskin,urticaria,tachycardia,and
hypotension. More serious manifestations include urticaria,
ﬂush, hypotension, bronchospasm, angioedema, shock, and
cardiac arrest. Many present with only one or two of these
features.Inmostcases,themorerapidtheonsetofsymptoms
is, the more severe the reaction is. It is very important to stop
the administration of the drug or agent at the earliest after
the onset of symptoms.
5. Diagnosisof Anaphylaxis
History of atopy is present in fewer than 50% of patients.
Clinical recognition of manifestations is very important.
Serial serum Tryptase estimations are helpful in diagnosis
of anaphylaxis [6]. Tryptase enzyme is released from mast
cells and it parallels histamine release. Peak concentrations
well above 20ng/mL indicate true anaphylaxis/anaphylactic
reaction. The peak value of tryptase in the serum occurs
between30minutesto6hoursafterananaphylacticreaction.
The value of skin tests, and especially the prick test, has
been shown in extensive studies [7]. This demonstrates the
presence of speciﬁc IgE antibodies. In our reported case,
elevatedTryptaselevelsandskintestconﬁrmedthediagnosis
and proved the allergen.
6. Treatment
Abrupt cessation of administration of medication is war-
ranted. Treatment should be aimed to maintain good
cardiorespiratory support. Epinephrine is the mainstay of
the treatment. Hypotension should be corrected by rapid
intravascular volume expanders like crystalloids. If colloid
is suspected to be the causative agent, it should be replaced
by a crystalloid. In patient with cardiovascular collapse,
additional doses of epinephrine may be needed. Severe
anaphylaxis during antepartum or intrapartum period can
result in severe maternal hypotension and this in turn can
lead to severe brain damage of the fetus as a consequence
of intrapartum hypoxia. Gei et al. reported use of conti-
nous infusion of Epinephrine to correct hypotension and
fetal bradycardia following anaphylactic shock secondary to
Ampicillin during labour [8]. Chaudhuri et al. have reported
an allergic reaction to Penicillin in a Primigravida who
needed incremental doses of epinephrine for stabilization of
bloodpressureandthebabywasdiagnosedwithneurological
damage [9]. In pregnant patients, continous electronic
fetal monitoring is advocated during the event as fetus is
very sensitive to maternal changes in blood pressure. The
treatment has been summarised in Table 2.
Studies in animals have demonstrated the generation
of nitric oxide during anaphylaxis. Inhibition of nitric
oxide synthase improves survival in an animal model of
anaphylaxis. Nitric oxide causes vasodilation indirectly by
increasing the activation of guanylyl cyclase. Methylene
blue is an inhibitor of guanylyl cyclase, which increases
systemic vascular resistance and reverses shock in animal
studies.Treatmentwithmethyleneblueshouldbeconsidered
in patients with anaphylactic hypotension that have not
responded to other interventions but there have been no
reports of its use in the peripartum period [10].
7. Discussion
Anaphylactic reactions to anaesthesia and associated agents
of anaphylaxis have been reported with increasing fre-
quency [11]. 2000–2002 Conﬁdential Enquiries into Mater-
nal Deaths in the United Kingdom looked into one of the
case reports and highlighted the “need for staﬀ to able
to manage anaphylaxis.” Volplex is a sterile solution of
chemically modiﬁed (succinylated) ﬂuid gelatin produced
from bovine collagen. This colloid is given as intravenous
infusion for the lost blood volume. All available colloid
volume substitutes carry the risk of anaphylactic reactions.
None of the colloids in clinical use (plasma protein solution,
gelatine, hydroxyethylstarch, and dextran) is free from the
risk of anaphylactic reactions. Even though the incidence
of anaphylactic reactions is low (0.03%), lethal outcome
might be encountered. Between the colloids diﬀerences exist
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system) and degree of severity of anaphylactic reactions
are concerned. Since the underlying pathomechanisms have
not been elucidated yet, true prophylactic measures are
unknown. Therefore, it is mandatory to control the patient
verycarefullyatthebeginningofinfusion;earlysymptomsof
anaphylactic reactions should trigger immediate therapeutic
measures. Studies of the adverse reactions to gelatin plasma
substitutes have concluded that, far from being inert sub-
stances, gelatins can initiate a life-threatening anaphylactic
response[12].AllergicreactiontoHydroxyethylstarch(acol-
loid)hasbeenreportedduringcaesareandelivery[13].Other
substances reported to cause anaphylaxis in pregnancy are
Laminaria insertion, Latex, Ranitidine, Antibiotics, sodium
ferric gluconate complex, Snake antivenom, insect stings,
local anaesthetics, and induction of general anesthesia [14–
20].
8. Conclusion
There must be a written emergency action plan for the
management of anaphylaxis. Accurate reporting and issue of
Medic-Alert is an important risk management issue. There
is no valid predictor of drug anaphylaxis. It is important to
analyze circumstances leading to anaphylaxis and maintain
fatal anaphylactic register in a national data base [21].
Anaphylaxis can result in signiﬁcant morbidity mainly
related to cerebral hypoxia after an ineﬀective resuscitation.
These reactions can be life threatening in particular if
adequate treatment is not started quickly. Since anaphylaxis
can occur with any drug, all the members of the perinatal
team should be familiar with the recognition of symptoms
and signs of anaphylactic reaction. Colloid solutions are
used very frequently for postpartum haemorrhage and
sometimes antenatally for severe haemorrhage. Anaphy-
laxis has been reported with commonly used substances
like latex, and very commonly used drugs like Oxytocin,
antibiotics, and Ranitidine. Colloid solution is a commonly
used plasma expander in clinical practice. This case report
further highlights the fact that anaphylactic reactions can be
unpredictable and severe reactions manifested in the form
of angioedema and cardiovascular collapse need immediate
and prompt treatment. As seen in the reported case, severe
anaphylactic reaction was well managed by the anaesthetist
as it happened during a surgical procedure. The importance
of awareness among the clinicians about the clinical signs
and treatment measures to be undertaken cannot be under-
estimated as reactions are being observed with commonly
used medications. Severe reactions require early recognition
and aggressive resuscitation. All obstetricians and midwives
should be trained to be able to identify and manage this
emergency. The team should also ensure the availability of
these drugs in the labour ward as well as in the antenatal and
postnatal wards. Every hospital should have a guideline for
anaphylaxis. This should be included in the Induction book
as part of protocols. Management of anaphylaxis should
be included in the emergency drills on a regular basis so
that uncommon life-threatening event is tackled in the most
eﬀective way.
Table 1: Clinical manifestations of drug hypersensitivity [22].
Cardiovascular symptoms 74.7%
Cutaneous symptoms 71.9%
Cardiovascular collapse 50.8%
Bronchospasm 39.8%
Hypotension 17.3%
Angioedema 12.3%
Cardiac arrest 5.9%
Table 2: Treatment of anaphylaxis [21].
(1) Stop administration of the drug(s) likely to have caused the
reaction.
(2) First line of treatment includes restoration of blood pressure by
making the patient lie ﬂat, raising the foot end and lateral tilt of the
patient if occurs antepartum.
(3) Maitain airway: give 100% oxygen.
(4) Adrenaline is given intramuscularly 0.5–1.0mg {0.5–1mL
adrenaline injection 1 in 1000}. This can be repeated every 10
minutes until improvement occurs. If hemodyanamic instability
persists, a continuous drip may be needed. One mg of epinephrine
is diluted in 250mL of saline, starts at 15mL/hr (1µg/mt), and
titrated according to clinical response.
(5) Administer crystalloid or colloid for rapid intravascular volume
expansion. If colloid has been given prior to the reaction, change to
crystalloid since the causative agent might have been the colloid.
Secondary therapy
(1) Antihistamine, for example, Chlorphenaramine over 1 minute
10–20mg diluted in a syringe with normal saline or water given
slowly intravenously.
(2) Corticosteroids (100–500mg Hydrocortisone IV) is of use in
severely aﬀected patients.
(3)Bronchodialatorsmayberequiredforpersistentbronchospasm.
(4) Prolonged monitoring in the Intensive care unit.
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